The global antifungal drug market is expected to register high growth in the forecoming years. Major factors driving growth of the global antifungal drug market, growing population, rising ageing population, increasing prevalence and incidence rate of fungal diseases. In addition, growing R&D activities coupled with increasing funding from the public & private sector is the factor expected to drive the growth of the global antifungal drug market.
The global antifungal drug market report has been segmented on the basis of drug type, route of administration, therapeutic indication, and region.
On the basis of drug type, the global antifungal drug market has been segmented into echinocandins, azoles, polyenes, allylamines and others.
On the basis of route of administration, the global antifungal drug market has been segmented into oral, parental, and topical.
On the basis of therapeutic indication, the global antifungal drug market has been segmented into aspergillosis, dermatophytosis, candidiasis, and others including blastomycosis, mucormycosis etc.
Request for the Sample Report Here: https://marketresearch.biz/report/antifungal-drug-market/request-sample/
On the basis of region, the global antifungal drug markets segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
In 2018, North America antifungal drug market is expected to account for major share in the global market in terms of revenue, and is expected to maintain its dominance over the forecast period, due to extensive research and development in the region for innovating better drugs. However, Asia Pacific antifungal drug market is projected to register highest CAGR in the next five years owing to rising incidence of fungal diseases in this region.
Key players operating in the global antifungal drug market include Pfizer Inc., Sanofi S.A, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Abbott Laboratories, Bayer AG, Scynexis Inc., Enzon Pharmaceuticals, Inc., and GlaxoSmithKline Plc.